New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
14:25 EDTVRTX, VRTX, VRTXLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech/Pharmaceuticals Analysts, along with Key Opinion Leaders (KOL) discuss, head of the data release, Vertex's Phase 3 TRAFFIC and TRANSPORT Phase 3 Studies on an Analyst/Industry conference call to be held on May 8 at 3 pm.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
06:14 EDTVRTXPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 18, 2015
09:04 EDTVRTXVertex data likely to show lung function improvement, says JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use